The startup develops bispecific antibodies that enhance potency and selectivity for complex diseases by utilizing a multi-step approach to select and design optimal antibodies. This technology targets high-expression levels on specific cells, addressing limitations in current therapies and improving treatment efficacy for unmet medical needs.
Funding
Funding not disclosed
Founders
Product
Problem
Current therapies for complex diseases, particularly in oncology, often lack sufficient potency and selectivity, leading to limited efficacy and potential off-target effects. Existing bispecific antibody approaches may face challenges in achieving optimal therapeutic windows and addressing the diverse expression levels of target antigens.
Solution
Virtuoso Therapeutics is developing a pipeline of novel bispecific antibodies engineered to enhance potency and selectivity in treating cancer and other serious diseases. Their approach leverages a "Guide x Effector" principle, pairing an effector arm with a guide arm that binds to targets with high expression levels specifically on target cells. This avidity-driven synthetic specificity aims to improve therapeutic outcomes by focusing the antibody's activity on the intended cells while minimizing off-target effects. The company's antibody engineering capabilities, combined with insights into target biology, enable the creation of bispecifics with differentiated product profiles.
Target Audience
The primary target audience includes patients with hematological malignancies and solid tumors who may not respond to current therapies or who could benefit from more selective and effective treatments.
Features
- "Guide x Effector" design principle to achieve avidity-driven synthetic specificity
- Function-guided bispecific format design
- Strong antibody discovery capabilities to ensure species cross-reactivity
- Access to multiple different bispecific formats
- Antibodies are engineered for high stability, good yield, and compatibility with conventional antibody purification and manufacturing processes
- Lead programs targeting CD38 and CD47, with additional programs in preclinical development